217 related articles for article (PubMed ID: 24844218)
1. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A
Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
Horiuchi A; Hayashi T; Kikuchi N; Hayashi A; Fuseya C; Shiozawa T; Konishi I
Int J Cancer; 2012 Oct; 131(8):1755-67. PubMed ID: 22287060
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Br J Cancer; 2008 Feb; 98(4):845-51. PubMed ID: 18231102
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
[TBL] [Abstract][Full Text] [Related]
6. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
Yan H; Qiu L; Xie X; Yang H; Liu Y; Lin X; Huang H
Oncol Rep; 2017 Mar; 37(3):1412-1418. PubMed ID: 28184931
[TBL] [Abstract][Full Text] [Related]
7. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
8. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
9. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
10. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
[TBL] [Abstract][Full Text] [Related]
12. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact.
Iborra S; Hirschfeld M; Jaeger M; Zur Hausen A; Braicu I; Sehouli J; Gitsch G; Stickeler E
Int J Gynecol Cancer; 2013 Jul; 23(6):990-6. PubMed ID: 23748175
[TBL] [Abstract][Full Text] [Related]
13. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
[TBL] [Abstract][Full Text] [Related]
14. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
15. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
16. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
18. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
19. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of galectin-7 in epithelial ovarian cancer.
Kim HJ; Jeon HK; Lee JK; Sung CO; Do IG; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Anticancer Res; 2013 Apr; 33(4):1555-61. PubMed ID: 23564797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
